CTCheng Tang

Cheng Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cheng Tang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoli Lan

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications
  • Yongkang Gai

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    4 shared publications
  • Fan Hu

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Tong Liu

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Weiwei Ruan

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Xiao Zhang

    Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications

Latest Publications

  • Open Access

    Data from Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers

    by Zhi Lin, Cheng Tang, Tong Liu, Xingyi Wang, Zaijie Wu, Fan Hu, Yongkang Gai, Weiwei Ruan, Xiao Zhang, Xiaoli Lan

    Purpose:The study aims to compare the diagnostic performance of the novel melanin-targeted [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]PFPN) positron emission tomography (PET) and [18F]fluorodeoxyglucose ([18F]FDG) PET in mucosal melanoma, evaluate their impact on clinical staging, and assess correlations between imaging metrics and molecular markers.Experimental Design:This prospective study enrolled 65 participants with histologically confirmed mucosal melanoma from February 2021 to January 2025. All participants underwent both [18F]FDG PET and [18F]PFPN PET within 1 week. Lesion- and participant-based analyses compared detection sensitivity, false-positive rate, and staging concordance. Quantitative PET parameters were analyzed, and correlations with HMB45, SOX10, MelanA, S100, and mutation status (BRAF, KIT, NRAS) were evaluated using nonparametric tests and correlation analysis with Bonferroni correction. Decision curve analysis was used to evaluate clinical benefit.Results:Sixty-five participants were included. [18F]PFPN PET showed higher lesion-based sensitivity than [18F]FDG PET [363/399 (91%) vs. 332/399 (83.2%)] and no false positives [0/363 (0%) vs. 4/336 (1.2%)]. The normalized maximum standardized uptake value was significantly higher for [18F]PFPN across all lesion types (P < 0.05). PFPN-based staging was more consistent with clinical staging (6.2% vs. 18.5% discordant cases). [18F]PFPN uptake showed significant positive correlations with HMB45 and SOX10 expression, whereas [18F]FDG parameters showed no such associations.Conclusions:[18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.

  • Decoupling Alzheimer Disease Pathologic Abnormalities at PET with Improved Clinical Relevance by Interpretable Adversarial Decomposition Learning

    by Cheng Tang, Xun Sun, Anqi Tang, Weiwei Ruan, Fang Liu, Hanyi Fang, Yongkang Gai, Zhihou Liang, Ying Su, Xinggang Wang, et al.

    An interpretable, Alzheimer disease–specific pathophysiologic-constrained adversarial decomposition framework yielded voxel-level pathologic maps and an artificial intelligence biomarker with stronger cross-sectional and temporal associations with cognition and hippocampal volume than standard PET biomarkers.


  • Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers

    by Zhi Lin, Cheng Tang, Tong Liu, Xingyi Wang, Zaijie Wu, Fan Hu, Yongkang Gai, Weiwei Ruan, Xiao Zhang, Xiaoli Lan

    Purpose: The study aims to compare the diagnostic performance of the novel melanin-targeted [18F]-N-(2-(diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)picolinamide ([18F]PFPN) positron emission tomography (PET) and [18F]fluorodeoxyglucose ([18F]FDG) PET in mucosal melanoma, evaluate their impact on clinical staging, and assess correlations between imaging metrics and molecular markers. Experimental Design: This prospective study enrolled 65 participants with histologically confirmed mucosal melanoma from February 2021 to January 2025. All participants underwent both [18F]FDG PET and [18F]PFPN PET within 1 week. Lesion- and participant-based analyses compared detection sensitivity, false-positive rate, and staging concordance. Quantitative PET parameters were analyzed, and correlations with HMB45, SOX10, MelanA, S100, and mutation status (BRAF, KIT, NRAS) were evaluated using nonparametric tests and correlation analysis with Bonferroni correction. Decision curve analysis was used to evaluate clinical benefit. Results: Sixty-five participants were included. [18F]PFPN PET showed higher lesion-based sensitivity than [18F]FDG PET [363/399 (91%) vs. 332/399 (83.2%)] and no false positives [0/363 (0%) vs. 4/336 (1.2%)]. The normalized maximum standardized uptake value was significantly higher for [18F]PFPN across all lesion types (P < 0.05). PFPN-based staging was more consistent with clinical staging (6.2% vs. 18.5% discordant cases). [18F]PFPN uptake showed significant positive correlations with HMB45 and SOX10 expression, whereas [18F]FDG parameters showed no such associations. Conclusions: [18F]PFPN PET outperforms [18F]FDG PET in lesion detection and clinical staging in mucosal melanoma, especially for liver and bone metastases. Its association with melanin differentiation markers may support its use in personalized imaging strategies.